| Literature DB >> 34322366 |
Renee J Dufault1, Mesay M Wolle2, H M Skip Kingston1, Steven G Gilbert1, Joseph A Murray3.
Abstract
Pre-natal and post-natal chemical exposures and co-exposures from a variety of sources including contaminated air, water, soil, and food are common and associated with poorer birth and child health outcomes. Poor diet is a contributing factor in the development of child behavioral disorders. Child behavior and learning can be adversely impacted when gene expression is altered by dietary transcription factors such as zinc insufficiency or deficiency or by exposure to toxic substances permitted in our food supply such as mercury, lead, or organophosphate pesticide residue. Children with autism spectrum disorder and attention deficit hyperactivity disorders exhibit decreased or impaired PON1 gene activity which is needed by the body to metabolize and excrete neurotoxic organophosphate pesticides. In this current review we present an updated macroepigenetic model that explains how dietary inorganic mercury and lead exposures from unhealthy diet may lead to elevated blood mercury and/or lead levels and the development of symptoms associated with the autism and attention deficit-hyperactivity disorders. PON1 gene activity may be suppressed by inadequate dietary calcium, selenium, and fatty acid intake or exposures to lead or mercury. The model may assist clinicians in diagnosing and treating the symptoms associated with these childhood neurodevelopmental disorders. Recommendations for future research are provided based on the updated model and review of recently published literature. ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.Entities:
Keywords: Attention deficit hyperactivity disorder; Autism; Inorganic mercury; Lead; Paraoxonase 1; Selenium
Year: 2021 PMID: 34322366 PMCID: PMC8299913 DOI: 10.5662/wjm.v11.i4.144
Source DB: PubMed Journal: World J Methodol ISSN: 2222-0682
Figure 1Macroepigenetic model for role of unhealthy diet in mercury and lead toxicity. ASD: Autism spectrum disorder; ADHD: Attention deficit hyperactivity disorder.
Summary of methods for the determination of blood Hg and Pb measurements
|
|
|
|
|
|
| Hg | Blood (20-30 mL) | CV-AAS | NA | [ |
| Red blood cells | NA | [ | ||
| Blood (3-5 mL) | NA | [ | ||
| Red blood cells (0.4 mL), plasma (0.5 mL) | 0.09 ng/mL | [ | ||
| Hg | Blood | CV-AFS | 0.09 μg/L | [ |
| Blood (0.5 g) | 0.001 μg/L | [ | ||
| Hg | Blood (20 mL) | DMA | 0.01 μg/L | [ |
| Pb | Blood (3-5 mL) | AAS | NA | [ |
| Blood (3 mL) | 25.01 µg/L | [ | ||
| Blood (3-5 mL) | NA | [ | ||
| Blood (3-5 mL) | 0.03 μg/dL | [ | ||
| Pb | Blood | GF-AAS | 2.85 μg/dL | [ |
| Blood (20-30 mL) | NA | [ | ||
| Blood (50 µL) | 0.042 μg/dL | [ | ||
| Blood (20 mL) | 0.01 μg/dL | [ | ||
| Blood | NA | [ | ||
| Blood (0.5-2 mL) | 25 μg/L | [ | ||
| Pb | Bone | X-ray fluorescence | 2 µg/g | [ |
| Hg, Pb | Blood (1 mL), hair (5-10 mg) | ICP-MS | NA | [ |
| Blood (2-3 mL) | 0.25 μg/L (Hg) | [ | ||
| Blood (2-3 mL) | 0.25 μg/dL (Pb) | [ | ||
| Blood (20-30 mL) | 0.1 μg/L (Hg) | [ | ||
| Blood (20-30 mL) | 0.002 μg/dL (Pb) | [ | ||
| Blood | 1.3 μg/dL (Pb) | [ | ||
| Blood | 0.24 μg/L (Hg) | [ | ||
| Blood (20 mL) | 0.3 μg/dL (Pb) | [ | ||
| Hg, Pb | Blood (46 µL) | DBS with ICP-MS | 0.65 μg/L (Hg) | [ |
| Blood (46 µL) | 0.27 μg/dL (Pb) | [ | ||
| Blood (30 µL) | NA | [ | ||
| Blood (50 µL) | 0.13 ppb | [ | ||
| Blood (50 µL) | 2.38 ppb | [ | ||
| Blood (6.2 µL) | 0.7 μg/L (Hg) | [ | ||
| Methylmercury | Blood (0.5 g) | GC-CV-AFS | 0.0001 μg/L | [ |
| Dental amalgam | NA | [ | ||
| Blood (0.5 mL) | 0.1 pg/L | [ | ||
| I-Hg, methylmercury | Blood (0.5 g) | GC-ICP-MS with SIDMS | NA | [ |
| I-Hg, methylmercury | Blood (35-50 µL) | DBS with GC-CV-AFS | 0.3 μg/L (methylmercury) | [ |
| Blood (40-60 µL) | 1.9 μg/L (I-Hg) | [ | ||
| Blood (40-60 µL) | [ |
Sample size unspecified.
Lowest detected concentration reported in the study (limit of detection not available).
NA: Limit of detection and lowest detected concentration not available; CV-AAS: Cold vapor atomic absorption spectrometry; CV-AFS: CV-AAS to atomic fluorescence spectrometry; DMA: Direct mercury analysis; AAS: Atomic absorption spectrometry; GF-AAS: Graphite furnace AAS; ICP-MS: Inductively coupled plasma mass spectrometry; SIDMS: Speciated isotope dilution mass spectrometry; DBS: Dried blood spot.